Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Desai resigns as chief of Apotex

Executive Summary

Apotex chief executive officer and president, Jeremy Desai, has “resigned to pursue other opportunities”, with immediate effect. Jeff Watson – previously president of Global Generics – has been appointed as president and chief operating officer with responsibility for “day-to-day operations for the company on a global basis”, while vice-chairman Jack Kay will also assume the role of chief executive officer, having previously held the role before Desai’s appointment.

You may also be interested in...



Wave Of New Leaders Could Reshape Generics Industry

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

In Quick Succession: Wave Of New Leaders Could Reshape Industry

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

A New Era: Apotex Gets Fresh Leadership As SK Completes Acquisition

As SK Capital Partners completes its acquisition of Apotex, generics industry veteran Allan Oberman has been named as the new president and CEO of the Canadian giant, replacing Jeff Watson who will remain on the company’s board.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

GB000286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel